Pacira Pharmaceuticals (NASDAQ:PCRX)‘s stock had its “buy” rating reaffirmed by Wedbush in a research note issued to investors on Friday.

Several other equities research analysts have also commented on PCRX. Oppenheimer started coverage on shares of Pacira Pharmaceuticals in a report on Thursday, September 7th. They issued a “market perform” rating for the company. CIBC started coverage on shares of Pacira Pharmaceuticals in a report on Thursday, September 7th. They issued a “market perform” rating for the company. Jefferies Group restated a “buy” rating and issued a $59.00 price target on shares of Pacira Pharmaceuticals in a report on Thursday, September 7th. Mizuho restated a “buy” rating and issued a $53.00 price target on shares of Pacira Pharmaceuticals in a report on Monday, September 25th. Finally, Needham & Company LLC restated a “buy” rating on shares of Pacira Pharmaceuticals in a report on Tuesday, September 26th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $49.00.

Pacira Pharmaceuticals (NASDAQ:PCRX) traded down $0.45 during trading on Friday, reaching $42.45. 751,300 shares of the company’s stock traded hands, compared to its average volume of 1,132,725. The stock has a market cap of $1,720.00, a PE ratio of -32.40 and a beta of 2.20. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.24 and a current ratio of 6.99. Pacira Pharmaceuticals has a 12 month low of $29.81 and a 12 month high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings data on Wednesday, November 8th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The company had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $68.99 million. During the same period in the previous year, the company earned $0.20 EPS. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. research analysts predict that Pacira Pharmaceuticals will post -0.85 earnings per share for the current year.

In related news, Director Mark A. Kronenfeld purchased 1,000 shares of the business’s stock in a transaction on Friday, November 10th. The shares were acquired at an average price of $41.60 per share, for a total transaction of $41,600.00. Following the purchase, the director now owns 6,795 shares of the company’s stock, valued at approximately $282,672. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP James B. Jones sold 850 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $41.11, for a total transaction of $34,943.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 70,075 shares of company stock valued at $2,707,452. 6.60% of the stock is currently owned by company insiders.

Institutional investors have recently modified their holdings of the business. Oppenheimer Asset Management Inc. acquired a new position in Pacira Pharmaceuticals during the 2nd quarter valued at approximately $114,000. Cubist Systematic Strategies LLC increased its stake in Pacira Pharmaceuticals by 121.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock valued at $152,000 after purchasing an additional 1,752 shares in the last quarter. QS Investors LLC acquired a new position in Pacira Pharmaceuticals during the 2nd quarter valued at approximately $157,000. Ameritas Investment Partners Inc. increased its stake in Pacira Pharmaceuticals by 9.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after purchasing an additional 302 shares in the last quarter. Finally, Spectrum Management Group Inc. acquired a new position in Pacira Pharmaceuticals during the 3rd quarter valued at approximately $166,000.

ILLEGAL ACTIVITY WARNING: “Pacira Pharmaceuticals (PCRX) Receives Buy Rating from Wedbush” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/05/pacira-pharmaceuticals-pcrx-receives-buy-rating-from-wedbush.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.